AstraZeneca Annual Report and Form 20-F Information 2008

Company Balance Sheet

At 31 December	Notes	2008 $m	2007 (restated) $m
Fixed assets Fixed asset investments	1	26,727	31,079
Current assets Debtors – other		1	1
Debtors – amounts owed by group undertakings		8,217	6,984
		8,218	6,985
Total assets		34,945	38,064
Creditors: Amounts falling due within one year Non-trade creditors	2	(414)	(4,353)
Interest bearing loans and borrowings	3	(650)	–
		(1,064)	(4,353)
Net current assets		7,154	2,632
Total assets less current liabilities		33,881	33,711
Creditors: Amounts falling due after more than one year Amounts owed to group undertakings	3	(283)	(283)
Interest bearing loans and borrowings	3	(10,255)	(10,482)
		(10,538)	(10,765)
Net assets		23,343	22,946
Capital and reserves
Called-up share capital	6	362	364
Share premium account	4	2,046	1,888
Capital redemption reserve	4	94	91
Other reserves	4	2,743	2,565
Profit and loss account	4	18,098	18,038
Shareholders’ funds	5	23,343	22,946

$m means millions of US dollars.

The Financial Statements comprising Company Balance Sheet, the Accounting Policies and Notes 1 to 8 were approved by the Board of Directors on 29 January 2009 and were signed on its behalf by:

DAVID R BRENNAN
Director

SIMON LOWTH
Director